related to a completed Phase 1 trial with Berubicin in GBM which Reata conducted in 2006. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. Its lead drug candidate, Berubicin, is proposed for the treatment of GBM, an aggressive and incurable form of brain cancer.
Berubicin treatment of brain cancer patients appeared to demonstrate positive responses that include one durable complete response in a Phase 1 human clinical trial conducted by Reata Pharmaceuticals, Inc.ĬNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Waldemar Priebe, the founder of the Company.īerubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents.
As previously announced, the pediatric trial will be conducted at Children's Memorial Health Institute, the largest pediatric hospital in Poland." WPD Pharmaceuticals, Inc. to commence a first-ever Phase 1 trial in children later this year. In addition, we expect WPD Pharmaceuticals, Inc. "We are looking forward to initiating our Phase 2 clinical trial in the second half of this year with our partner, WPD Pharmaceuticals, Inc.
Climaco, Chief Executive Officer of CNS Pharmaceuticals. "We are delighted to provide this update on Berubicin's potential capabilities given the unmet need for this aggressive disease," commented John M. This initial trial was conducted in 2006 and as of February 2020, the patient has remained cancer free for over 13 years. One patient experienced a durable complete response, which is defined by the National Cancer Institute as the disappearance of all signs of cancer in response to treatment. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. In the Phase 1 trial, 44% of patients experienced a statistically significant improvement in progression-free survival. GBM is an aggressive type of brain cancer and, currently, there are no effective therapies approved to treat this disease. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, announces as of February 2020, a patient from the Phase 1 clinical trial for the treatment of glioblastoma multiforme ("GBM"), conducted by Reata Pharmaceuticals, Inc., remains cancer free. HOUSTON, Ma/PRNewswire/ - CNS Pharmaceuticals, Inc.
0 kommentar(er)
